Vedanta Biosciences Announces $16.6 Million Series C-2 Financing
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced a $16.6 million Series C-2 financing round, bringing the total capital […]
